FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021799767> ?p ?o ?g. }

• W3021799767 abstract "Abstract Background It is widely hoped that personal cancer vaccines will extend the number of patients benefiting from checkpoint and other immunotherapies. However, it is clear creating such vaccines will be challenging. It requires obtaining and sequencing tumor DNA/RNA, predicting potentially immunogenic neoepitopes and manufacturing a one-use vaccine. This process takes time and considerable cost. Importantly, most mutations will not produce an immunogenic peptide and many patient’s tumors do not contain enough DNA mutations to make a vaccine. We have discovered that frameshift peptides (FSP) created from errors in the production of RNA rather than from DNA mutations are potentially a rich source of neoantigens for cancer vaccines. These errors are predictable, enabling the production of a FSP microarray. Previously we found that these microarrays can identify both personal and shared neoantigens. Here, we compared the performance of personal cancer vaccines (PCVs) with that of a shared antigen vaccine, termed Frameshift Antigen Shared Therapeutic (FAST) vaccine, using the 4 T1 breast cancer model. Sera from 4 T1-tumor bearing mice were assayed on the peptide microarray containing 200 Fs neoantigens, for the PCV, the top 10 candidates were select and personal vaccines constructed and administrated to the respective mice. For the FAST, we selected the top 10 candidates with higher prevalence among all the mice challenged. Seven to 12 days challenged mice were immunized, combined or not with immune checkpoint inhibitor (ICI) (αPD-L1 and αCTLA-4). Primary and secondary tumor clearance and growth were evaluated as well as cellular and humoral immune response against the vaccine targets by IFN-γ ELISPOT and ELISA. Lastly, we analyzed the immune response of the FAST-vaccinated mice by flow cytometry in comparison to the control group. Results We found that PCVs and FAST vaccines both reduced primary tumor incidence and growth as well as lung metastases when delivered as monotherapies or in combination with ICI. Additionally, the FAST vaccine induces a robust and effective T-cell response. Conclusions These results suggest that FSPs produced from RNA-based errors are potent neoantigens that could enable production of off-the-shelf shared antigen vaccines for solid tumors with efficacy comparable to that of PCVs." @default.
• W3021799767 created "2020-05-13" @default.
• W3021799767 creator A5003748765 @default.
• W3021799767 creator A5010394535 @default.
• W3021799767 creator A5018339730 @default.
• W3021799767 creator A5028419995 @default.
• W3021799767 creator A5034425452 @default.
• W3021799767 creator A5057209439 @default.
• W3021799767 creator A5059714191 @default.
• W3021799767 date "2020-05-05" @default.
• W3021799767 modified "2023-10-18" @default.
• W3021799767 title "Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model" @default.
• W3021799767 cites W1551407310 @default.
• W3021799767 cites W1965031244 @default.
• W3021799767 cites W1992125357 @default.
• W3021799767 cites W2007026865 @default.
• W3021799767 cites W2012437894 @default.
• W3021799767 cites W2053393698 @default.
• W3021799767 cites W2053725511 @default.
• W3021799767 cites W2054265941 @default.
• W3021799767 cites W2101571970 @default.
• W3021799767 cites W2308389558 @default.
• W3021799767 cites W2336879304 @default.
• W3021799767 cites W2554497406 @default.
• W3021799767 cites W2589191322 @default.
• W3021799767 cites W2616354594 @default.
• W3021799767 cites W2724264513 @default.
• W3021799767 cites W2725858612 @default.
• W3021799767 cites W2728365508 @default.
• W3021799767 cites W2749319028 @default.
• W3021799767 cites W2765521808 @default.
• W3021799767 cites W2885227878 @default.
• W3021799767 cites W2901151404 @default.
• W3021799767 cites W2903083041 @default.
• W3021799767 cites W2904210127 @default.
• W3021799767 cites W2904803926 @default.
• W3021799767 cites W2908702014 @default.
• W3021799767 cites W2914345456 @default.
• W3021799767 cites W2921452779 @default.
• W3021799767 cites W2954515247 @default.
• W3021799767 cites W2954615294 @default.
• W3021799767 cites W2991496740 @default.
• W3021799767 cites W3008186528 @default.
• W3021799767 doi "https://doi.org/10.1186/s12865-020-00350-3" @default.
• W3021799767 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7201681" @default.
• W3021799767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32370785" @default.
• W3021799767 hasPublicationYear "2020" @default.
• W3021799767 type Work @default.
• W3021799767 sameAs 3021799767 @default.
• W3021799767 citedByCount "6" @default.
• W3021799767 countsByYear W30217997672020 @default.
• W3021799767 countsByYear W30217997672022 @default.
• W3021799767 countsByYear W30217997672023 @default.
• W3021799767 crossrefType "journal-article" @default.
• W3021799767 hasAuthorship W3021799767A5003748765 @default.
• W3021799767 hasAuthorship W3021799767A5010394535 @default.
• W3021799767 hasAuthorship W3021799767A5018339730 @default.
• W3021799767 hasAuthorship W3021799767A5028419995 @default.
• W3021799767 hasAuthorship W3021799767A5034425452 @default.
• W3021799767 hasAuthorship W3021799767A5057209439 @default.
• W3021799767 hasAuthorship W3021799767A5059714191 @default.
• W3021799767 hasBestOaLocation W30217997671 @default.
• W3021799767 hasConcept C104317684 @default.
• W3021799767 hasConcept C121608353 @default.
• W3021799767 hasConcept C147483822 @default.
• W3021799767 hasConcept C150194340 @default.
• W3021799767 hasConcept C186836561 @default.
• W3021799767 hasConcept C203014093 @default.
• W3021799767 hasConcept C2777701055 @default.
• W3021799767 hasConcept C2778378633 @default.
• W3021799767 hasConcept C29906990 @default.
• W3021799767 hasConcept C501734568 @default.
• W3021799767 hasConcept C502942594 @default.
• W3021799767 hasConcept C54355233 @default.
• W3021799767 hasConcept C71924100 @default.
• W3021799767 hasConcept C86803240 @default.
• W3021799767 hasConcept C8891405 @default.
• W3021799767 hasConceptScore W3021799767C104317684 @default.
• W3021799767 hasConceptScore W3021799767C121608353 @default.
• W3021799767 hasConceptScore W3021799767C147483822 @default.
• W3021799767 hasConceptScore W3021799767C150194340 @default.
• W3021799767 hasConceptScore W3021799767C186836561 @default.
• W3021799767 hasConceptScore W3021799767C203014093 @default.
• W3021799767 hasConceptScore W3021799767C2777701055 @default.
• W3021799767 hasConceptScore W3021799767C2778378633 @default.
• W3021799767 hasConceptScore W3021799767C29906990 @default.
• W3021799767 hasConceptScore W3021799767C501734568 @default.
• W3021799767 hasConceptScore W3021799767C502942594 @default.
• W3021799767 hasConceptScore W3021799767C54355233 @default.
• W3021799767 hasConceptScore W3021799767C71924100 @default.
• W3021799767 hasConceptScore W3021799767C86803240 @default.
• W3021799767 hasConceptScore W3021799767C8891405 @default.
• W3021799767 hasIssue "1" @default.
• W3021799767 hasLocation W30217997671 @default.
• W3021799767 hasLocation W30217997672 @default.
• W3021799767 hasLocation W30217997673 @default.
• W3021799767 hasLocation W30217997674 @default.
• W3021799767 hasOpenAccess W3021799767 @default.
• W3021799767 hasPrimaryLocation W30217997671 @default.
• W3021799767 hasRelatedWork W1979444736 @default.

• next